Nebenwirkungen · Vantavo (previously Alendronate sodium and colecalciferol, MSD)
VANTAVO 70 mg/2800 IU tablets VANTAVO 70 mg/5,600 IU tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-212420 · Präparat HOS-154886
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-12T17:01:00Z · SHA-256 8af3d625a9b3263c85d9187ef982dc536a575a89ed66495cd9df07321ec43693 · Passage 42f7144177697b690f59b1bda795c3fd216297691cf296a2e1269a137feab3cd · Zeichen 4890–5245 im Abschnitt